Facioscapulohumeral Dystrophy (FSHD)

Facioscapulohumeral dystrophy (FSHD) is a genetic muscle disease. The name tells you which muscles are hit first: the face (facio-), the shoulder blades (scapulo-), and the upper arms (humeral). Over time, these muscles gradually become weaker and lose bulk. The pattern is often asymmetric, which means one side can be more affected than the other. Many people first notice shoulder blade “winging,” trouble lifting the arms overhead, or a flatter facial expression. Although the disease begins in these areas, other muscles (abdominal wall, lower legs, and hip girdle) can be involved as it progresses. Most people keep the ability to walk for many years, and life expectancy is usually near normal, but disability can vary widely. NCBIMuscular Dystrophy AssociationMuscular Dystrophy UK

Facioscapulohumeral muscular dystrophy—usually shortened to FSHD—is a genetic muscle condition that mainly weakens the face (facio-), shoulder blades (scapulo-), and upper arms (humeral). It typically starts in the teen or young-adult years but can appear in childhood or later life. Weakness is often asymmetric (one side worse than the other). People may notice shoulder blades that “wing,” trouble lifting the arms overhead, difficulty whistling or closing the eyes tightly, and later, foot-drop or trouble with stairs. Pain and fatigue are very common. Life expectancy is usually normal. AANEM

FSHD happens because a gene called DUX4, which is usually silent in adult muscle, becomes inappropriately switched on in muscle cells. When DUX4 is active in muscle, it disrupts normal muscle function, damages muscle fibers, and leads to weakness. This “mis-expression” of DUX4 is the final common pathway in FSHD. NCBIBioMed Centralfshdsociety.org

---

Types of FSHD

FSHD has two main genetic types, but they look the same in clinics and are diagnosed by different genetic mechanisms.

1) FSHD1.
This is the most common type (about 95%). A section of repeated DNA called D4Z4 on chromosome 4 (region 4q35) is shortened (“contracted”) and sits next to a special “permissive” tail of DNA known as the 4qA haplotype. This combination allows a stable DUX4 message to be made in muscle, which drives the disease. FSHD1 is usually autosomal dominant, which means a child has a 50–50 chance of inheriting it if one parent is affected, although new (“de novo”) cases can appear. NCBIBioMed Central

2) FSHD2.
This less common form (roughly 5%) does not have a short D4Z4 array. Instead, the D4Z4 region becomes too open (“hypomethylated”) because of changes in other genes that keep DNA tightly packed. The most frequent genes are SMCHD1, and more rarely DNMT3B and LRIF1. A permissive 4qA haplotype is still required. The end result is the same: DUX4 becomes active in muscle cells. BioMed CentralNCBI

Infantile / early-onset FSHD.
When FSHD begins in childhood, weakness is often faster and can be linked with hearing loss and retinal blood vessel problems (Coats-like vasculopathy) in a small subset, especially when the D4Z4 block is very short. Patient InfoAAO

---

Cause

Important note: in FSHD, “causes” are genetic and epigenetic mechanisms that let the DUX4 gene turn on in muscle. Lifestyle or injuries do not cause FSHD, although fitness and therapy can influence how you function day to day.

1. DUX4 mis-expression in muscle is the final common cause. When this gene turns on in adult muscle, it harms muscle fibers. BioMed Centralfshdsociety.org

2. D4Z4 repeat contraction on 4q35 (FSHD1). Shortening to a small number of repeats removes natural silencing and makes it easier for DUX4 to be expressed. NCBI

3. Permissive 4qA haplotype. This DNA “tail” contains a polyadenylation signal that stabilizes the DUX4 message; without it, disease does not occur. NCBI

4. Hypomethylation (too little chemical tagging) at D4Z4. Less methylation loosens chromatin and promotes DUX4 activation. Lower methylation also correlates with more severe weakness. BioMed CentralAmerican Academy of Neurology

5. SMCHD1 gene variants (FSHD2 and modifiers of FSHD1). When this gene is reduced, D4Z4 is less repressed, which allows DUX4 to turn on. NCBIBioMed Central

6. DNMT3B gene variants (rare FSHD2). This DNA-methylating gene helps keep D4Z4 quiet; variants can reduce methylation and lift repression. BioMed Central

7. LRIF1 gene variants (rare FSHD2). This protein participates in the repressive complex that keeps D4Z4 closed; variants can weaken that repression. BioMed Central

8. 3D chromatin relaxation at 4q35. The physical opening of this region favors DUX4 transcription. BioMed Central

9. Very short D4Z4 arrays in FSHD1. Extremely short arrays are linked with earlier onset and risk of retinal complications in a minority. AAO

10. Allele-specific methylation differences. The “disease” chromosome can show particularly low methylation, pushing the balance toward DUX4 expression. PMC

11. De novo (new) D4Z4 contractions. Some people develop FSHD1 without an affected parent because the contraction happens in the egg or sperm. NCBI

12. Somatic mosaicism. A D4Z4 contraction that occurs early after conception can leave some cells “affected” and others not, shifting severity and detection. NCBI

13. Trans-acting modifier load. The combined effect of variants in SMCHD1/DNMT3B/LRIF1 and possibly other chromatin regulators (e.g., CTCF, DNMT1, DNMT3A, EZH2, SUV39H1) can tune disease severity. Frontiers

14. Repeat range with reduced penetrance (8–10 units). At the border of “short,” some FSHD1 arrays cause variable expression and incomplete penetrance. American Academy of Neurology

15. 4q/10q repeat homology. Only 4qA repeats are disease-permissive; similar repeats on chromosome 10 are usually non-permissive, but rare rearrangements can confuse testing and biology. BioMed Central

16. Age-dependent penetrance. The genetic change is present at birth, but symptoms often emerge and accumulate with age because of biology, not behavior. NCBI

17. Asymmetric muscle involvement. While not a “cause,” the built-in asymmetry reflects how DUX4-related damage and muscle susceptibility vary across the body. ScienceDirect

18. Sex and hormonal context. Men and women can both be affected, but expression and severity can differ between individuals for reasons that include modifier genes and epigenetics. NCBI

19. Family transmission (autosomal dominant). A single affected copy is enough to cause disease; inheritance patterns shape who is at risk in a family. NCBI

20. Epigenetic “threshold” model. FSHD is best understood as crossing a molecular threshold where DUX4 becomes stable in muscle; different genetic paths can push a person past that threshold. BioMed Central

---

Common symptoms

1. Shoulder blade winging. The shoulder blades lift and stick out because the muscles that hold them against the rib cage are weak. This makes lifting the arms hard. Muscular Dystrophy AssociationMuscular Dystrophy UK

2. Trouble lifting the arms overhead. Weakness of the deltoid, trapezius, and serratus anterior makes reaching up tiring or impossible. Muscular Dystrophy Association

3. Facial weakness. Smiling, whistling, puffing cheeks, or tight eye closure can be difficult, so the face may appear flatter or “less expressive.” Muscular Dystrophy UK

4. Asymmetric weakness. One side is often noticeably weaker, which is a hallmark pattern in FSHD. ScienceDirect

5. Upper-arm weakness. Lifting, carrying, or combing hair becomes hard because the upper-arm muscles lose strength. Muscular Dystrophy Association

6. Abdominal wall weakness. The belly can push forward, and the umbilicus may move upward when sitting up (Beevor’s sign), showing selective abdominal weakness. NCBI

7. Lower-leg weakness and foot drop (later). The muscles that lift the foot can weaken, causing tripping or a slapping gait. Muscular Dystrophy UK

8. Hip girdle weakness. Getting up from a low chair or climbing stairs can feel heavy and slow as pelvic muscles weaken. Muscular Dystrophy Association

9. Back muscle weakness with sway back. Paraspinal and abdominal weakness can cause lumbar lordosis and fatigue in the lower back. NCBI

10. Muscle pain. Many people report aching shoulders or upper-back pain due to weak stabilizers and overworked remaining muscles. NCBI

11. Fatigue. Moving with weaker muscles takes more energy, so daily activities can be exhausting even when heart and lungs are normal. NCBI

12. Hearing loss (in a small subset, mainly early-onset). High-frequency sensorineural hearing loss can occur, especially in childhood-onset disease. Patient Info

13. Retinal blood vessel problems (rare). A few children with severe FSHD develop Coats-like retinal vasculopathy, which needs eye screening and care. AAO

14. Breathing muscle weakness (uncommon overall). Some people—especially with more advanced disease—develop respiratory muscle weakness and may need monitoring. American Academy of Neurology

15. Swallowing or speech fatigue (sometimes). Facial and shoulder-girdle involvement can spill into bulbar strain, leading to tiredness with long talking or chewing. NCBI

---

Diagnostic tests

How doctors confirm FSHD: Diagnosis blends clinical pattern recognition with genetic testing. Muscle enzymes and EMG can support the picture, but DNA-based testing is the gold standard because it directly checks the mechanism that turns on DUX4.

A) Physical examination (bedside observation)

1. Inspection for scapular winging. The clinician watches the shoulder blades at rest and during forward push; winging strongly suggests shoulder-girdle weakness typical of FSHD. Muscular Dystrophy Association

2. Facial strength testing. The person is asked to close eyes tightly, puff cheeks, purse lips, whistle, or smile broadly; subtle asymmetry and weakness support FSHD. Muscular Dystrophy UK

3. Beevor’s sign. While the person tries to sit up from supine, the belly button moves upward, indicating selective lower-abdominal weakness common in FSHD. NCBI

4. Gait and posture assessment. The examiner looks for foot drop, a steppage gait, and increased lumbar lordosis—all compatible with FSHD involvement. Muscular Dystrophy UK

B) Manual / functional tests

5. Manual Muscle Testing (MMT). The examiner grades strength of face, scapular stabilizers, deltoid, biceps, hip abductors, and ankle dorsiflexors to map the pattern and track change over time. NCBI

6. Scapular fixation maneuver. Stabilizing the scapula while re-testing deltoid strength clarifies how much winging is limiting arm elevation versus pure deltoid weakness. NCBI

7. Timed functional measures. Timed up-and-go, 10-meter walk, sit-to-stand, or stair climb quantify day-to-day ability and are useful for monitoring. NCBI

8. Heel-toe walking test. This simple check looks for subtle foot drop or calf weakness as the person walks on heels and then toes. Muscular Dystrophy UK

C) Laboratory and pathological tests

9. Serum creatine kinase (CK). CK is often normal or only mildly elevated in FSHD, which helps distinguish it from more inflammatory myopathies. NCBI

10. Targeted FSHD1 genetic test (D4Z4 repeat sizing + 4q haplotype). Modern labs size the D4Z4 array on chromosome 4 and confirm the 4qA “permissive” haplotype. Historically this used Southern blot; newer methods include optical genome mapping (OGM) and long-read approaches. PMC+1

11. FSHD2 testing (methylation + gene sequencing). Labs measure D4Z4 methylation (looking for hypomethylation) and sequence SMCHD1, DNMT3B, and LRIF1 to confirm the FSHD2 pathway. BioMed CentralBioMed Central

12. Allele-specific methylation profiling. Newer platforms can test methylation on each 4qA allele separately, improving accuracy and genotype-phenotype prediction. PMC

13. Next-generation sequencing panels for muscular dystrophy. These can identify coexisting genetic factors or rule out mimics when the picture is unclear. PMC

14. Muscle biopsy (now uncommon for FSHD). If genetic tests are inconclusive, a biopsy may show a chronic myopathy pattern, but it is not specific for FSHD; genetics is preferred when possible. NCBI

D) Electrodiagnostic tests

15. Needle electromyography (EMG). EMG usually shows a myopathic pattern (short-duration, low-amplitude motor unit potentials). It supports the diagnosis and helps exclude neuropathic causes of weakness. NCBI

16. Nerve conduction studies (NCS). These are generally normal in FSHD and help rule out nerve disorders that can also cause shoulder or foot weakness. NCBI

17. Repetitive nerve stimulation (when myasthenia is a mimic). If fluctuating weakness suggests a neuromuscular junction problem, this test helps exclude it, since FSHD is a muscle fiber disease. NCBI

E) Imaging tests

18. Muscle MRI of shoulders, trunk, and legs. MRI maps exactly which muscles are fatty-replaced or inflamed. The pattern in FSHD (e.g., trapezius, serratus anterior, and other scapular stabilizers early; selective thigh/calf involvement later) helps with diagnosis and tracking. NCBI

19. Muscle ultrasound. Ultrasound can show increased echo intensity from fatty change and is a fast, radiation-free way to follow superficial muscles over time. NCBI

20. Ophthalmic imaging for retinal vasculopathy in early-onset cases. Dilated retinal exam and, when needed, fluorescein angiography look for Coats-like changes so treatment can protect vision in the rare children at risk. AAO

Non-pharmacological treatments (therapies & other strategies)

Below are evidence-based, everyday tools. For each, you’ll see (Description • Purpose • How it helps).

1. Individualized aerobic exercise (low to moderate intensity)
   Description: Regular cycling, brisk walking, arm-crank, or pool walking 3–5 days/week, 20–40 minutes at a pace that raises breathing but allows conversation.
   Purpose: Improve stamina, walking speed, and daily function without harming muscle.
   How it helps: Multiple randomized and controlled trials in FSHD show aerobic training safely improves fitness and performance (VO₂peak, workload, walking speed), with no signs of muscle damage. Start low; build slowly with a therapist. PubMedPMC

2. Strength training (light-to-moderate, supervised)
   Description: Small sets for key muscle groups (deltoids often spared; work legs, core, shoulder stabilizers) 2–3 times/week.
   Purpose: Maintain strength, posture, and joint protection.
   How it helps: Evidence suggests no harm in FSHD; benefits are modest and individualized. Avoid heavy eccentric loads; focus on quality of movement. PubMed

3. High-intensity interval training (selected patients, supervised)
   Description: Short bursts (e.g., 1–2 minutes) at higher effort with longer easy periods; total 20–30 minutes.
   Purpose: Boost cardiovascular fitness efficiently.
   How it helps: Trials in FSHD report improved fitness when carefully dosed and monitored. Not for everyone; discuss with your team. MDPI

4. Physical therapy (PT) program
   Description: Tailored plan covering stretching, gentle strengthening, pacing, and posture.
   Purpose: Reduce pain, protect joints, and maintain safe mobility.
   How it helps: PT is a standard pillar of care recommended by neuromuscular guidelines; therapists also teach energy conservation and fall-prevention skills. AANEM

5. Occupational therapy (OT)
   Description: Strategies and gadgets for dressing, grooming, cooking, computer work.
   Purpose: Keep independence at home, school, and work.
   How it helps: Compensatory techniques and adaptive equipment cut fatigue and strain on weak muscles. AANEM

6. Scapular bracing (non-surgical support)
   Description: Custom shoulder/upper-back braces to limit winging.
   Purpose: Improve arm reach and reduce ache from unstable shoulder blades.
   How it helps: Provides external stabilization; may help mild cases or those not ready for surgery. AANEM

7. Ankle-foot orthosis (AFO) for foot-drop
   Description: Lightweight brace to hold the foot up during swing phase.
   Purpose: Prevent trips and falls; improve walking safety.
   How it helps: Simple, high-value aid in many neuromuscular conditions with dorsiflexor weakness. AANEM

8. Aquatic therapy
   Description: Exercise in warm water with buoyancy.
   Purpose: Move more with less joint load and fatigue.
   How it helps: Water offloads body weight, making gait practice and shoulder work more comfortable. AANEM

9. Energy conservation & pacing
   Description: Plan the day, alternate tasks, sit for chores, use carts and power tools.
   Purpose: Prevent “push-crash” fatigue cycles.
   How it helps: Conserves limited muscle capacity for what matters most; a core OT skill. AANEM

10. Pain self-management skills
    Description: Heat/ice, gentle myofascial release, TENS (if appropriate), relaxation breathing, and graded activity.
    Purpose: Reduce musculoskeletal pain and muscle guarding.
    How it helps: FSHD has a high prevalence of pain; routine, multimodal strategies make a difference day-to-day. AANEM

11. Sleep and posture care
    Description: Supportive pillows, side-lying to reduce shoulder strain, consistent sleep routine.
    Purpose: Improve recovery and daytime energy.
    How it helps: Better sleep reduces pain sensitivity and fatigue perception. AANEM

12. Eye surface protection for incomplete eyelid closure
    Description: Lubricating eye gels/ointments at night; moisture chamber goggles.
    Purpose: Prevent dry-eye damage when eyelids don’t fully close.
    How it helps: Protects the cornea and improves comfort; seek urgent care if vision changes occur. AANEM

13. Audiology support (especially in early-onset FSHD)
    Description: Baseline and follow-up hearing tests; hearing aids when needed.
    Purpose: Protect language development in children; improve communication for adults.
    How it helps: Hearing loss occurs in a subset—particularly with large deletions—so proactive checks matter. AANEM

14. Ophthalmology screening
    Description: Dilated retinal exams in higher-risk patients (very large deletions, childhood onset).
    Purpose: Detect Coats-like exudative retinopathy early.
    How it helps: Retinal disease is rare but potentially vision-threatening and treatable when caught. AANEM

15. Breathing health plan (for those with advanced weakness)
    Description: Periodic PFTs, cough-assist teaching, vaccination, and sleep-disordered breathing screening.
    Purpose: Prevent and manage restrictive breathing problems.
    How it helps: Clinically significant respiratory failure is uncommon, but monitoring prevents late surprises. AANEM

16. Workstation & home ergonomics
    Description: Adjust desk height, use voice-to-text, pick light tools, use reachers.
    Purpose: Reduce shoulder load and neck/back pain.
    How it helps: Better leverage and less overhead work protect vulnerable muscles. AANEM

17. Safe mobility tech
    Description: Trekking poles, rollators, power assist wheels, or scooters for distance.
    Purpose: Stay active without overtaxing calves or hip flexors.
    How it helps: Extends community mobility and reduces fall risk. AANEM

18. Mental health & CBT for fatigue/pain
    Description: Cognitive-behavioral therapy, pacing coaching, and support groups.
    Purpose: Tackle fatigue, mood, and coping.
    How it helps: A trial program (FACTS-2-FSHD) was designed to reduce chronic fatigue through aerobic training plus CBT principles. BioMed Central

19. Genetic counseling & family planning
    Description: Discuss inheritance, testing options for relatives, and reproductive choices.
    Purpose: Provide clear information and support.
    How it helps: FSHD is typically autosomal dominant, with variable expressivity; counseling reduces uncertainty. AANEM

20. Community, advocacy, and research participation
    Description: Engage with FSHD groups and registries.
    Purpose: Access expert resources and potential trials.
    How it helps: Keeps you up to date and connected to care pathways. AANEM

---

Drug treatments

There is no approved medication that stops or reverses FSHD today. Medicines are used to treat symptoms like pain, sleep issues, or anxiety, and to prevent complications. Always individualize doses with your clinician—especially if you have kidney, liver, stomach, or heart conditions. AANEM

1. Acetaminophen (Paracetamol) – analgesic/antipyretic
   Dose (adults): 500–1,000 mg as needed every 6–8 hours; typical max 3,000 mg/day (or 4,000 mg/day if advised by clinician).
   Purpose: First-line for musculoskeletal pain.
   How it works: Central pain modulation; gentle on the stomach.
   Side effects: Usually mild; liver toxicity if overdosed or mixed with alcohol.

2. NSAIDs: Ibuprofen or Naproxen – anti-inflammatory analgesics
   Dose: Ibuprofen 200–400 mg every 6–8 hours; Naproxen 250–500 mg twice daily.
   Purpose: Flare-ups of shoulder/back pain from overuse or posture strain.
   Mechanism: COX inhibition lowers prostaglandins → less inflammation/pain.
   Side effects: Stomach irritation/ulcer, kidney strain, blood pressure elevation; avoid in certain heart/kidney conditions.

3. Topical NSAIDs (e.g., diclofenac gel) – localized pain relief
   Dose: As labeled (often 2–4 g up to 4×/day).
   Purpose: Shoulder girdle or knee pain with fewer systemic risks.
   Mechanism: Local COX inhibition in tissues under the skin.
   Side effects: Local skin irritation; minimal systemic exposure.

4. Duloxetine – serotonin–norepinephrine reuptake inhibitor
   Dose: 30 mg daily → 60 mg daily.
   Purpose: Chronic musculoskeletal or neuropathic-type pain; may also aid mood.
   Mechanism: Enhances pain inhibitory pathways in the spinal cord.
   Side effects: Nausea, dry mouth, sleep changes; avoid with certain drug interactions.

5. Amitriptyline (low dose at night) – tricyclic antidepressant
   Dose: 10–25 mg nightly; titrate slowly.
   Purpose: Pain plus sleep maintenance problems.
   Mechanism: Modulates pain transmission; improves sleep continuity.
   Side effects: Morning grogginess, dry mouth, constipation; caution in older adults.

6. Gabapentin – antiepileptic for neuropathic pain
   Dose: 100–300 mg at night → up to 300 mg 3×/day as tolerated.
   Purpose: Burning or shooting pain; sleep aid via sedation.
   Mechanism: Reduces calcium-channel–mediated neurotransmitter release.
   Side effects: Drowsiness, dizziness; dose adjust in kidney disease.

7. Pregabalin – antiepileptic for neuropathic pain
   Dose: 50–75 mg twice daily → up to 150–300 mg/day.
   Purpose: Similar to gabapentin; often simpler titration.
   Mechanism/side effects: As above; may cause edema or weight gain.

8. Topical lidocaine 5% patches
   Dose: Apply to focal painful area up to 12 h/day.
   Purpose: Localized shoulder or low-back pain spots.
   Mechanism: Numbs superficial nerves; reduces abnormal firing.
   Side effects: Local skin irritation.

9. Melatonin – sleep-regulation aid
   Dose: 1–5 mg 30–60 min before bedtime.
   Purpose: Improve sleep onset/maintenance when pain/fatigue disrupt nights.
   Mechanism: Resets circadian signaling.
   Side effects: Morning grogginess in some; choose consistent timing.

10. Short-course muscle spasm relievers (if needed) – e.g., baclofen or tizanidine
    Dose: Baclofen 5–10 mg 1–3×/day; Tizanidine 2–4 mg at night; use sparingly.
    Purpose: Painful guarding/spasm around weak shoulders or back.
    Mechanism: Central muscle-relaxant action decreases reflex muscle tone.
    Side effects: Sedation, dizziness; can worsen weakness if overused.

Not recommended as disease therapy: past studies of albuterol and other agents haven’t shown meaningful, consistent benefit on strength or function in FSHD; guidelines emphasize exercise and supportive care rather than chronic “muscle drugs.” AANEM

---

Dietary molecular supplements

Evidence for supplements in FSHD specifically is limited; some have broader neuromuscular data. Think “supportive,” not curative. Discuss interactions (e.g., with anticoagulants or diabetes meds). MDPI

1. Creatine monohydrate
   Dose: 3–5 g/day (optional loading 20 g/day split for 5–7 days).
   Function: Supports quick energy in muscle (phosphocreatine system).
   Mechanism: Increases phosphocreatine stores; may improve training responses.
   Evidence: Helps strength/lean mass in several myopathies; data in FSHD are small but suggest feasibility/safety. MDPI

2. Vitamin D₃ (cholecalciferol)
   Dose: Often 1,000–2,000 IU/day (or per blood levels).
   Function: Bone health, immune regulation.
   Mechanism: Improves calcium absorption; supports bone in reduced-mobility states. MDPI

3. Calcium (diet first, supplement if needed)
   Dose: Typically 1,000–1,200 mg/day from diet ± supplement.
   Function/Mechanism: Partner with vitamin D to maintain bone mineral density.

4. Omega-3 fatty acids (EPA/DHA)
   Dose: ~1–3 g/day combined EPA+DHA (check anticoagulant use).
   Function: Anti-inflammatory milieu; cardiovascular support.
   Mechanism: Resolvin/protectin pathways modulate inflammation. MDPI

5. Coenzyme Q10 (ubiquinone)
   Dose: 100–300 mg/day with food.
   Function: Mitochondrial electron transport support.
   Mechanism: Acts in oxidative phosphorylation and as an antioxidant. MDPI

6. L-Carnitine
   Dose: 1–3 g/day in divided doses.
   Function: Fatty-acid transport into mitochondria; may help fatigue in some neuromuscular disorders.
   Mechanism: Carnitine shuttle cofactor. MDPI

7. Magnesium
   Dose: 200–400 mg elemental/day (citrate or glycinate forms often gentler).
   Function: Muscle relaxation; cramp reduction in some.
   Mechanism: Modulates neuromuscular excitability.

8. Whey or plant protein (as food)
   Dose: 20–30 g after training; aim for ~1.0–1.2 g/kg/day total protein unless told otherwise.
   Function: Stimulates muscle protein synthesis post-exercise.
   Mechanism: Provides essential amino acids, including leucine “trigger.” MDPI

9. Curcumin (with piperine for absorption)
   Dose: 500–1,000 mg/day standardized extract.
   Function: General anti-inflammatory effects; joint comfort.
   Mechanism: NF-κB pathway modulation. (Evidence in FSHD is preliminary.) MDPI

10. B-vitamin repletion (if low)
    Dose: Based on labs (B12, folate).
    Function: Corrects deficiencies that worsen fatigue or neuropathy symptoms.
    Mechanism: Supports energy metabolism and nerve function.

---

Regenerative / stem-cell / immune-type” therapies

Bottom line: There are no approved stem-cell or “immunity booster” drugs for FSHD. Several investigational approaches are in trials; unregulated stem-cell clinics should be avoided. U.S. Food and Drug Administration

1. Del-brax (AOC 1020, Avidity Biosciences) – investigational siRNA therapy
   What it is: An antibody–oligonucleotide conjugate that delivers siRNA against DUX4 mRNA into muscle via the transferrin receptor.
   Mechanism: RNA interference to silence DUX4, aiming to slow or halt disease biology.
   Dosing in trials: Step-up dosing 1 mg/kg then 2 mg/kg; later cohorts at 4 mg/kg (Phase 1/2 FORTITUDE).
   Status: Interim data show >50% reductions in DUX4-regulated gene panels and acceptable safety; not approved. aviditybiosciences.com

2. Losmapimod – p38α/β MAPK inhibitor (Fulcrum Therapeutics)
   Mechanism: p38 pathway inhibition intended to reduce DUX4 program activation.
   Dosing studied: 15 mg twice daily for 48 weeks in Phase 3 REACH.
   Status: Phase 3 did not show benefit over placebo on primary or key secondary outcomes; not approved. mdaconference.org

3. Other antisense/siRNA strategies to DUX4 – preclinical/early clinical
   Concept: Oligonucleotides that bind DUX4 transcripts to prevent translation.
   Status: Early pipeline beyond AOC 1020; no approvals yet. (Mechanism aligns with #1.) aviditybiosciences.com

4. Gene-regulation approaches (e.g., epigenetic/CRISPR-based repression)
   Concept: Re-silence the D4Z4 region or directly repress DUX4 expression in muscle nuclei.
   Status: Research stage; no approved therapies as of August 2025. (Clinical proof pending.) AANEM

5. Myostatin/activin-pathway inhibitors
   Concept: Increase muscle mass/strength by blocking negative regulators of muscle growth.
   Status: Not established for FSHD; no approvals specific to FSHD as of 2025. (General mechanism only.) AANEM

6. “Stem-cell injections” marketed by clinics
   Warning: Not FDA-approved for FSHD; reports include serious harms (infections, tumor formation, blindness) from unapproved “regenerative” products. Consider only within regulated clinical trials. U.S. Food and Drug Administration

---

Surgeries

1. Scapulothoracic arthrodesis (scapular fixation)
   Procedure: The shoulder blade is surgically attached to the rib cage with wires/plates to stop winging.
   Why: To restore a stable base so the deltoid can lift the arm higher; improves appearance and daily arm use.
   Evidence & caveats: Systematic review shows improved forward elevation/abduction and ADLs; complications ~41% overall (serious ~10%—e.g., hardware failure, non-union, pneumothorax). Careful selection and expert centers are essential. PMC

2. Tendon or soft-tissue procedures for shoulder positioning
   Procedure: Less common soft-tissue stabilizations in selected cases.
   Why: For patients not candidates for fusion but needing partial stabilization.
   Note: Outcomes are less robust than arthrodesis; discuss pros/cons thoroughly. PMC

3. Eyelid procedures for incomplete closure
   Procedure: Gold-weight implants or small tarsorrhaphy to help the eyelids close.
   Why: Protect the cornea from drying and injury; improve comfort/function. AANEM

4. Retinal laser/cryotherapy (Coats-like disease)
   Procedure: Ophthalmic laser or other retinal therapies when exudative changes threaten vision.
   Why: To preserve sight if retinal vasculopathy arises. AANEM

5. Foot-drop surgery (selected)
   Procedure: Tendon transfer or ankle stabilization in refractory falls despite bracing.
   Why: Improve toe-clearance and safety in carefully chosen cases. AANEM

---

Prevention priorities

1. Exercise smart: keep up regular low-to-moderate aerobic work; add gentle strength work. Avoid extreme, unaccustomed eccentric lifting. PubMed

2. Protect shoulders: minimize overhead tasks; use step-stools, long-handled tools. AANEM

3. Fall-proofing: use AFOs/trekking poles, remove home trip hazards, add night lights. AANEM

4. Bone health: adequate vitamin D and calcium; weight-bearing as tolerated. MDPI

5. Vaccinations: annual flu and up-to-date pneumonia shots to prevent respiratory setbacks. AANEM

6. Eye care: nightly lubricating gel if eyes don’t fully close; urgent eye visit for flashes/floaters or vision change. AANEM

7. Hearing care (kids/early-onset): screen early; fit aids promptly if needed. AANEM

8. Weight management: keep a healthy weight to reduce load on weak muscles/joints. AANEM

9. Ergonomics: optimize workstation; consider voice input. AANEM

10. Avoid unproven “stem-cell” clinics: stick to regulated clinical trials only. U.S. Food and Drug Administration

---

When to see a doctor—don’t wait

• Sudden vision symptoms (flashes, floaters, vision loss) or eye pain. AANEM

• New or worsening hearing problems in a child with FSHD or early-onset disease. AANEM

• Breathing issues, morning headaches, or loud snoring—possible sleep-related breathing disorder. AANEM

• Rapid drop in function, frequent falls, or severe shoulder pain. AANEM

• Considering surgery or pregnancy—plan proactively with your neuromuscular team. AANEM

---

What to eat” and “what to avoid”

1. Do eat: lean proteins (fish, eggs, legumes) spaced through the day to support muscle repair—especially after exercise. Avoid: ultra-processed meats high in salt/saturated fat that strain heart/metabolic health. MDPI

2. Do eat: colorful fruits/vegetables (antioxidants, fiber). Avoid: sugary drinks/energy drinks that spike and crash energy. MDPI

3. Do eat: whole grains for steady energy. Avoid: heavy fried foods before activity (can worsen fatigue and reflux). MDPI

4. Do eat: omega-3-rich foods (salmon, sardines, walnuts). Avoid: excess omega-6 oils and deep-fried snacks. MDPI

5. Do eat: dairy or fortified alternatives for calcium/vitamin D. Avoid: chronically skipping calcium/vitamin D in low-mobility states. MDPI

6. Do use: creatine monohydrate (if your clinician agrees) to support training days. Avoid: multi-ingredient “muscle boosters” with stimulants. MDPI

7. Do hydrate throughout the day. Avoid: alcohol excess; it worsens balance, sleep, and recovery.

8. Do consider: magnesium-rich foods (greens, nuts). Avoid: megadoses of magnesium without supervision (can cause diarrhea/low blood pressure).

9. Do choose: high-fiber meals for gut health. Avoid: large late-night meals that worsen sleep.

10. Do plan: small, frequent meals on high-fatigue days. Avoid: long fasting that leads to energy crashes.

---

Frequently asked questions

1) Is FSHD life-shortening?
For most people, life expectancy is normal. The condition mainly affects muscle function; careful monitoring manages uncommon complications. AANEM

2) Will exercise make me worse?
Not when planned and progressed sensibly. Trials show aerobic training is safe and improves fitness in FSHD. Start low, go slow, and work with PT. PubMedPMC

3) What about heavy weightlifting?
Avoid sudden, heavy, eccentric-dominant lifting. Prefer light-to-moderate loads with excellent form and longer rest. PubMed

4) Do I need routine heart tests?
No, unless you have symptoms. Routine cardiac screening isn’t recommended in otherwise asymptomatic FSHD. AANEM

5) Can FSHD affect breathing?
Significant respiratory involvement is uncommon, but people with severe weakness should have periodic PFTs and vaccination to prevent infections. AANEM

6) Should my child get hearing checks?
Yes—especially with early-onset FSHD or very large deletions—because hearing loss can affect speech development if missed. AANEM

7) Why do my shoulders ache so much?
Winging deprives the deltoid of a stable base, so ordinary activities overwork muscles and joints. Bracing, PT, pacing, and (for some) scapular fixation surgery help. PMC

8) Is scapular fusion worth it?
In well-selected patients, it improves arm elevation and daily activities but has meaningful complication risks—choose experienced centers and review alternatives. PMC

9) Are there medicines that slow FSHD?
No approved disease-modifying drugs yet. Trials like losmapimod did not meet endpoints; new DUX4-targeting siRNA approaches (e.g., del-brax/AOC 1020) are experimental. mdaconference.orgaviditybiosciences.com

10) Do supplements help?
Some (e.g., creatine) can support training and muscle energy, but none treat FSHD. Use as adjuncts after discussing safety with your clinician. MDPI

11) Should I worry about my eyes?
Most people never develop retinal problems, but rare Coats-like disease can threaten vision—get dilated eye exams if you’re higher risk or if symptoms arise. AANEM

12) Can I have a normal pregnancy?
Many do well with routine obstetric care and PT input. Plan ahead; genetic counseling can help discuss inheritance. AANEM

13) Are stem-cell injections available?
Not legally for FSHD outside regulated trials. The FDA warns of serious harms from unapproved products; avoid commercial clinics. U.S. Food and Drug Administration

14) How common is pain?
Very common (surveys suggest up to ~79% report pain). Treat it proactively with multimodal strategies. AANEM

15) What’s the best long-term plan?
A multidisciplinary approach: steady aerobic activity, gentle strength, braces/tech as needed, symptom-targeted meds, bone/eye/hearing care, and periodic checks for breathing—plus staying engaged with reputable research. AANEM

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 17, 2025.